Not Signed In -
Cirrhosis |
Cirrhosis (Primary Biliary); Cirrhosis of the Liver; Liver Cirrhosis |
Clinical Trial: Adult-to-Adult Living Donor Liver Transplantation Study
This study is currently recruiting patients.
Purpose
There are two principal purposes of this study: 1) to determine whether it is more beneficial for a liver transplant recipient candidate to pursue a living donor liver transplant (LDLT) or wait for a deceased donor liver transplant (DDLT), and 2) to study the impact of liver donation on the donor's health and quality of life.
| Condition |
|---|
| Cirrhosis Hepatitis C Hepatocellular Carcinoma |
MedlinePlus related topics: Hepatitis C; Liver Cancer
Study Type: Observational
Study Design: Natural History, Longitudinal, Defined Population, Retrospective/Prospective Study
Official Title: Adult-to-Adult Living Donor Liver Transplantation Cohort Study
Expected Total Enrollment: 2470
Study start: October 2004; Expected completion: July 2009
Last follow-up: July 2008; Data entry closure: December 2008
Adult to adult living donor liver transplantation (LDLT) is a relatively new procedure increasingly used at major transplantation centers. Relatively small numbers of cases are performed at any one center and approaches to the patient and donor are too diverse across centers to provide reliable and generalizable information on donor and recipient outcomes from individual centers. Therefore, a network of nine leading liver transplantation centers and a data coordination center (DCC) has been organized to accrue and follow sufficient numbers of patients being considered for and undergoing LDLT to provide generalizable results from adequately powered studies. This network has established the Adult to Adult Living Donor Liver Transplantation Cohort Study (A2ALL) that will conduct both retrospective and prospective studies of LDLT.
The primary study objective is to analyze the effect of choosing to pursue living liver donation. The principal hypothesis is that pursuit of a living liver allograft leads to decreased pre-transplant morbidity and mortality and better long term outcomes for patients starting from the point at which listed patients have a potential donor evaluated (at least a history and physical examination). Emerging data suggest that LDLT provides an inferior graft because of reduced parenchymal mass and added technical complexity when compared to a whole liver used for DDLT. The magnitude of the disadvantage to the LDLT graft will be assessed by comparing results between LDLT and DDLT from the time of transplant. Finally, a careful and detailed series of studies of potential and actual living liver donors is included as a primary objective because of the tremendous importance of this issue to our understanding of the impact of the procedure.
Secondary objectives will address selected biological and clinical issues in transplantation structured around the comparison between DDLT and LDLT.
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
Inclusion Criteria - Potential Recipients:
- Potential recipient listed for single organ (liver) transplantation
- Patient is eligible for LDLT
- Age ≥ 18 years old at the time of donor history and physical exam
- Indication for transplant: non-fulminant liver disease
- Potential donor scheduled for evaluation (history and physical examination) within four weeks
Location and Contact Information
Peg Hill-Callahan, BS, LSW 734-998-6618 peghc@umich.edu
California
University of California Los Angeles, Los Angeles, California, 90095-7054, United States; Recruiting
R. Mark Ghobrial, MD, Principal Investigator
Ronald W. Busuttil, MD, Sub-Investigator
University of California San Francisco, San Francisco, California, 94143-0538, United States; Recruiting
Chris Freise, MD, Principal Investigator
Norah Terrault, MD, Sub-Investigator
Colorado
University of Colorado Health System, Denver, Colorado, 80262, United States; Recruiting
James Trotter, MD, Principal Investigator
Igal Kam, MD, Sub-Investigator
Illinois
Northwestern University, Chicago, Illinois, 60611, United States; Recruiting
Michael Abecassis, MD, Principal Investigator
Andreas Blei, MD, Sub-Investigator
New York
Columbia University, New York, New York, 10032, United States; Recruiting
Jean Emond, MD, Principal Investigator
Robert S Brown, MD, Sub-Investigator
North Carolina
University of North Carolina, Chapel Hill, North Carolina, 27599-7210, United States; Recruiting
Roshan Shrestha, MD, Principal Investigator
Jeffrey Fair, MD, Sub-Investigator
Pennsylvania
Univerisity of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States; Recruiting
Abraham Shaked, MD, Principal Investigator
Kim Olthoff, MD, Sub-Investigator
Virginia
University of Virginia, Charlottesville, Virginia, 22908-0708, United States; Recruiting
Carl L Berg, MD, Principal Investigator
Timothy Pruett, MD, Sub-Investigator
Virginia Commonwealth University, Richmond, Virginia, 23219, United States; Recruiting
Robert A Fisher, MD, Principal Investigator
Mitchell Shiffman, MD, Sub-Investigator
Robert M Merion, MD, Study Chair, University of Michigan - A2ALL Data Coordinating Center
Carl L Berg, MD, Study Chair, University of Virginia Health System
Jean Emond, MD, Study Chair, Columbia University
More Information
Adult-to-Adult Living Donor Liver Transplantation Cohort Study
Record last reviewed: November 2004
Last Updated: November 12, 2004
Record first received: November 12, 2004
ClinicalTrials.gov Identifier: NCT00096733
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 8, 2005
Resources
- Alcohol Alert #42. Alcohol and the Liver (National Institute on Alcohol Abuse and Alcoholism)
- Alcoholic Hepatitis (Mayo Foundation for Medical Education and Research)
email this page
print this page
bookmark this page
feedback on this page
